Blair Julie M, Zhou Hong, Seibel Markus J, Dunstan Colin R
ANZAC Research Institute, University of Sydney, NSW, Australia.
Nat Clin Pract Oncol. 2006 Jan;3(1):41-9. doi: 10.1038/ncponc0381.
The discovery of osteoprotegerin, receptor activator of nuclear factor kappa B (RANK) and RANK ligand as critical molecular determinants of osteoclastogenesis and regulators of bone resorption, has revolutionized our understanding of the processes of normal and pathological bone biology. Altering the relative biological availabilities of these molecules has direct consequences for the regulation of both bone resorption and bone remodeling. Importantly, recent research suggests a pivotal role for these molecules in mediating cancer-induced bone destruction. This review summarizes the current evidence of osteoprotegerin, RANK ligand and RANK involvement in the pathophysiology of skeletal metastasis, and of therapeutic targeting of this process.
骨保护素、核因子κB受体激活剂（RANK）和RANK配体作为破骨细胞生成的关键分子决定因素及骨吸收调节剂的发现，彻底改变了我们对正常和病理骨生物学过程的理解。改变这些分子的相对生物学有效性对骨吸收和骨重塑的调节都有直接影响。重要的是，最近的研究表明这些分子在介导癌症诱导的骨破坏中起关键作用。本综述总结了目前关于骨保护素、RANK配体和RANK参与骨转移病理生理学以及该过程治疗靶点的证据。
Zotero 插件